Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting
December 08, 2019 09:00 ET
|
Karyopharm Therapeutics Inc.
-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with...
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting
December 07, 2019 09:00 ET
|
Karyopharm Therapeutics Inc.
-- All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst® and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst®-Naïve and Revlimid®-Relapsed or...
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 02, 2019 16:05 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting
November 06, 2019 10:12 ET
|
Karyopharm Therapeutics Inc.
-- Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple...
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
November 04, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
− XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine − − Achieved XPOVIO® U.S. Net Product Sales of $12.8 Million with Over 500 Prescriptions Fulfilled as of...
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 01, 2019 16:58 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
Karyopharm to Report Third Quarter 2019 Financial Results on November 4, 2019
October 28, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report third quarter 2019...
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 01, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s...
Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million
September 16, 2019 07:00 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced its entry into a royalty agreement with...
Karyopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma Workshop
September 13, 2019 18:30 ET
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that five abstracts highlighting clinical...